© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m
Posted 12th March 2015

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m

NULL

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m
Image

Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell for USD25m

Orgenesis Inc., a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes, today announced the Company’s plan to increase its global presence and capabilities by acquiring MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies, Belgium.  

Orgenesis entered into a share exchange agreement with MaSTherCell SA and Cell Therapy Holding SA (collectively “MaSTherCell”) and each of the shareholders of the MaSTherCell, which provides for the acquisition by the Company of all of the issued and outstanding shares of MaSTherCell in exchange for the issuance of $24,593,000 in value of shares of common stock in the capital of the Company.

“The acquisition of MaSTherCell creates incremental value for both companies in business-critical ways.  First, it allows us to accelerate the transition of our lead product, Autologous Insulin Producing Cells (AIPCs) being developed as a therapeutic for Type 1 Diabetes, from pre-clinical testing into clinical trials.  Second, the acquisition will also allow us to diversify our business model and future product offering,” said Vered Caplan, chairperson and CEO of Orgenesis.  “We are creating a vertically integrated company that will deliver more end-user value and generate a stronger financial position for our overall business.  Both businesses will remain operationally independent, but will become strategically aligned in ways that maximize technical, financial and management synergies.  As a result of the acquisition, Orgenesis benefits from deeper involvement in the manufacturing process and resulting cost of goods efficiencies, while MaSTherCell benefits by expanding its international presence and by gaining access to public markets and financing for further technology-based investment.”

Orgenesis is an innovator in the technology of “cellular trans-differentiation.”  This process involves re-programming one adult cell type to function like an adult cell of a different type.  In the case of AIPCs, the company is transforming a type 1 diabetic patient’s own liver cells into insulin-producing cells. Cellular trans-differentiation is accomplished through a complex biologic process, requiring sophisticated manufacturing technology and capabilities.  MaSTherCell has in place a best-in-class combination of the process development capabilities and fully closed and tightly controlled GMP systems required to deliver commercial-scale manufacturing for Orgenesis.  Prior to the acquisition, the two companies have already been working together under a strategic manufacturing agreement.  With the acquisition in place, MaSTherCell will provide services not only to Orgenesis, but will continue to provide broad Contract Development and Manufacturing Services to other cell-based therapeutic companies around the world.

“Cell therapy developments have gained strategic significance in recent years – particularly in the areas of regenerative medicine, ex-vivo gene therapy and immunotherapy of cancer,” said Hugues Bultot, CEO of MaSTherCell.  “Research and scientific development in these sectors has seen rapid progress and because of our ability to innovate, our industrialization and manufacturing expertise has not only kept pace with, but has actually led in terms of the ability of our technology to meet the needs of rapidly evolving science.  Moving forward with Orgenesis, we will continue to provide for our current clients the same unique services but with a larger geographic reach.  By combing our organizations, we will be able to more quickly capitalize on our desires to expand our cell-based therapeutic contract development and manufacturing services internationally.  And, importantly, having access to public markets will enhance our ability to invest in the continued evolution of our technology and capabilities.”

For more information about either company, please visit www.orgenesis.com and www.masthercell.com

Categories: Finance, M&A


You Might Also Like
Read Full PostRead - Eye Icon
How to Maximise Business Opportunities with AI and Automation
Innovation
24/05/2023How to Maximise Business Opportunities with AI and Automation

Whether it be for operational heavy lifting or data management and analysis, AI and automation tools have the power to transform UK businesses.

Read Full PostRead - Eye Icon
How to Get Business Finance with a Poor Credit Score
News
10/06/2022How to Get Business Finance with a Poor Credit Score

If you have previously dealt with poor credit in your personal life, then getting finance for your business through your bank might be difficult, if not impossible when first starting your company. The good news is that you do not have to let a poor personal c

Read Full PostRead - Eye Icon
Make the Invisible Visible: AI-Based Investigation Solutions
News
13/02/2024Make the Invisible Visible: AI-Based Investigation Solutions

Established in 2012, Voyager Labs is an award-winning global leader in the development of advanced digital analytic solutions that enable public safety organizations to identify threats, mitigate risk, and fight crime.

Read Full PostRead - Eye Icon
5 Common Pitfalls of Freight Shipping Companies and How to Avoid Them
News
29/09/20225 Common Pitfalls of Freight Shipping Companies and How to Avoid Them

Freight shipping companies play an important role in moving cargo from one point to another and ensuring that both the cargo and its owners’ interests are properly safeguarded. Unfortunately, freight shipping companies are also vulnerable to many common mist

Read Full PostRead - Eye Icon
Hyper-short-term investments: what are millennials investing in?
Finance
02/09/2019Hyper-short-term investments: what are millennials investing in?

Despite the stereotype of the younger generation being frivolous with their money, it seems they are actually one of the savviest generations when it comes to turning a profit on their own. While they are hesitant to invest in stocks, millennials and generatio

Read Full PostRead - Eye Icon
How to Securely Invest in Businesses That Do Well During a Pandemic
Finance
21/07/2021How to Securely Invest in Businesses That Do Well During a Pandemic

The Covid-19 pandemic has caused immeasurable harm to businesses. However, there are some that are thriving. Find out where best to invest now.

Read Full PostRead - Eye Icon
Franklin advises Altice for the sale of stakes
M&A
25/06/2018Franklin advises Altice for the sale of stakes

Franklin advises Altice for the sale of stakes in its French and Portuguese telecom tower business

Read Full PostRead - Eye Icon
How to Overcome Major AWS DevOps Adoption Challenges
Innovation
21/11/2023How to Overcome Major AWS DevOps Adoption Challenges

Companies continue implementing DevOps practices and tools to streamline software development. According to the DevOps Pulse 2023 report from Logz.io, 45% of companies state they have implemented DevOps, which is a 7% increase compared to 2022. AWS DevOps tool

Read Full PostRead - Eye Icon
Nationwide Ranked as a Five-Star Business in Latest Corporate Responsibility Index
Finance
21/04/2015Nationwide Ranked as a Five-Star Business in Latest Corporate Responsibility Index

Nationwide has been awarded Business in the Community's highest five-star ranking in its annual benchmark of responsible business – the Corporate Responsibility Index (CR Index).



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow